CopyPastehas never been so tasty!

The Pharmaceutical Market : Czech Republic

by anonymous

  • 0
  • 0
  • 0
72 views

The Czech Republic is the second richest country in Central & Eastern Europe in per capita terms, and the third richest in terms of total GDP. According to the Economist Intelligence Unit (EIU), the economy was expected to grow 2.0% in 2011, following increases in 2010 and 2009. Spending on healthcare is expected to rise gradually over the next few years, leading to slow growth in overall healthcare expenditure. Private expenditure will represent a quarter of the total, one of the lowest expenditures in the region. http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/the-pharmaceutical-market-czech-republic.html

The United States Trade Representative removed the Czech Republic from its Special 301 Watch List in 2010, due to significant progress made in border control and the introduction in January 2010 of a new criminal code which raised the maximum penalties for IPR related crimes from two to eight years imprisonment. The legal environment is generally in line with EU legislation and patent terms of 20 years are provided for product claims and pipeline protection, although the law is not retroactive. New medicines legislation, Law 115/2007, came into force in December 2007 and new regulations concerning pricing and reimbursement came into force in January 2008, bringing the system into line with the EU Transparency Directive.

The Czech Republic pharmaceutical market is the second largest in the region, twice the size of Slovakia. A moderate CAGR is expected over the 2011-2016 period. The market is driven by strong import growth. However, the economy was not expected to grow significantly in 2011 and this may have tempered the overall growth rate of the pharmaceutical market. Generics account for around a third of the pharmaceutical market in value terms and just over half the market in volume terms, as they are cheaper and more likely to be reimbursed.

Espicom's highly-regarded world pharmaceutical market research reports provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

Market size and trends impacting the development of the market.

Five-year projections for market indicators such as health spending.
Regulations on drug applications & approvals, pricing & reimbursement as well as wholesaling and retail.
Specialised intelligence on generics and biological medicines.
Foreign and local company profiles

EXECUTIVE SUMMARY. 1
Snapshot: Strategic Espicom Analysis.2
Snapshot: Key Data Projections .3
MACROENVIRONMENT 4
POLITICAL4
ECONOMIC ...5
Projections ...5
LEGAL..6
EU Patent Protection & Intellectual Property Rights6
Proposal for Unitary Patent 6
National Patent Protection & Intellectual Property Rights 6
EU Supplementary Protection Certificates.6
EU Data Exclusivity6
DEMOGRAPHIC 7
Projections ...7
Demographic Indicators.8
Births.... 8
Deaths. 8
Infant Deaths 8
Life Expectancy at Birth. 8
EPIDEMIOLOGY.. 9
DISEASE BURDEN..9
Leading Causes of Death 9
DISEASE PREVALENCE..10
Communicable Diseases....10
HIV/AIDS. 10
Non-Communicable Diseases11
Cancer 11
Diabetes. 11
HEALTHCARE - ACCOMPANYING HEALTH STATISTICS .. 12
EU DIRECTIVE..12
Cross-Border Healthcare Directive ..12
ORGANISATION...12
EXPENDITURE.13
Projections .13
Latest Figures..14
Social Security.14
INFRASTRUCTURE....16
Hospital Infrastructure .16
Ambulatory Infrastructure17
SERVICES17
Hospital Inpatient Services ....17
Outpatient Services..18
WORKFORCE...19
Projections .19
Physicians...20
Nurses....20
REGULATORY AFFAIRS ... 21
EU REGULATORY AUTHORITY....21
NATIONAL AUTHORITY21
MARKETING REGISTRATION..21
EU Marketing Registration21
Centralised Procedure.. 21
National Regulation.22
Clinical Trials....22
Post Marketing Surveillance .22
PROMOTION .. 23
Advertising.23
PRICING & REIMBURSEMENT... 24
EU NETWORKING MEETING...24
NM CAPR24
NATIONAL REGULATION...24
PRICING .24
Drug Companies Sue the Government...24
REIMBURSEMENT ... 25
DISTRIBUTION CHANNELS.. 26
EU DIRECTIVE..26
Falsified Medicines Directive..26
DRUG WHOLESALING...26
DRUG RETAILING.26
MARKET ANALYSIS 27
SIZE....27
Projections .27
Historical Figures.29
Current Structure.30
PRODUCT DEVELOPMENT31
EU Programmes...31
Horizon 2020... 31
IMI.. 31
National Product Development..31
MANUFACTURING....32
TRADE ....35
Exports ..35
Imports..38
Parallel Imports... 41
Balance of Trade ..42
COMPETITION... 43
TRADE ASSOCIATION....43
AIFP....43
TRADE FAIRS...43
Pragomedica...43
COMPANY INTELLIGENCE 44
Farmak....44
Glenmark Pharmaceuticals (formerly Medicamenta)...44
ICN Czech Republic (formerly VUAB) .44
Teva Czech Industries (formerly IVAX CR)....44
Zentiva....45
OTC PHARMACEUTICALS48
REGULATION.. 48
MARKET SIZE.. 48
GENERIC PHARMACEUTICALS . 49
REGULATION.. 49
EU Marketing Registration49
MARKET SIZE.. 49
COMPETITION 49
Trade Association 49
CAFF...49
BIOLOGICS & BIOSIMILARS. 50
REGULATION.. 50
EU Approval Process.50
EU Regulation of Biosimilars .50
EMA Guideline Documents51
Draft Biosimilar Concept Paper. 51
Biosimilar mAb Guideline. 51
Biosimilars Approved in the EU...51
MARKET SIZE...52
COMPETITION.52
Trade Associations....52
CzechBio.52
Company Intelligence...53
Institute of Biotechnology53
Institute of Experimental Medicine....53
CONCLUSIONS: OPPORTUNITIES & CHALLENGES .... 54
Strategic Espicom Analysis... 54
MACROENVIRONMENT..54
EPIDEMIOLOGY....54
HEALTHCARE...54
REGULATORY AFFAIRS...55
PRICING & REIMBURSEMENT..55
DISTRIBUTION CHANNELS .56
MARKET.56
COMPETITION .56
OTC PHARMACEUTICALS....57
GENERIC PHARMACEUTICALS.57
BIOLOGICS & BIOSIMILARS57
Radar Analysis59
SWOT Analysis59
DIRECTORY ..60
GOVERNMENT ORGANISATIONS... 60
PHARMACEUTICAL PRODUCERS ... 60
BIOLOGIC & BIOSIMILAR COMPANIES.... 60
TRADE ORGANISATIONS.. 60

For more information kindly visit :
The Pharmaceutical Market : Czech Republic

Or

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Fax: + 91 22 27812290
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: https://twitter.com/BharatBook
Our Blogs: http://in.linkedin.com/pub/bharat-book/3a/98/512
http://financemarketreports.blogspot.com/

Add A Comment: